Dr. Reddy’s launches Sumatriptan Injection USP, Autoinjector System

26 Feb 2014 Evaluate

Dr. Reddy’s Laboratories has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 ml, for Subcutaneous Use, a therapeutic equivalent generic version of IMITREX STATdose Pen (sumatriptan succinate) 6 mg/0.5 ml in the US market on February 25, 2014, following the approval by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Sumatriptan Injection USP, Autoinjector System 6 mg/ 0.5 ml is available in a carton containing 2 single-dose prefilled syringes.

The IMITREX STATdose Pen (sumatriptan succinate) brand and generic combined had US sales of approximately $169 Million MAT for the most recent twelve months ending in December 2013 according to IMS Health.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1235.15 18.00 (1.48%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×